Jade Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Jade Biosciences, Inc. (JBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2025-03-27
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-09-30 was 4.40%, a 7.32% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-06-30 was 3.80%, a 11.76% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 4.28%, a 67.84% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-09-30 was 4.10%, a 272.73% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.50%, a 6.25% decline from fiscal 2023.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.80%, a 11.63% increase from fiscal 2022.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.30%, a 207.14% increase from fiscal 2021.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.40%, a 6.67% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2024-12-31 | 4.50% 10-K · filed 2025-03-27 | |||
| 2023-12-31 | 4.80% 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 4.40% 10-Q · filed 2023-11-13 | 4.40% 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | 3.80% 10-Q · filed 2023-08-14 | 4.30% 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | 4.28% 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 4.30% 10-K · filed 2024-03-25 | |||
| 2022-09-30 | 4.10% 10-Q · filed 2023-11-13 | 4.10% 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | 3.40% 10-Q · filed 2023-08-14 | 3.40% 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | 2.55% 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | 1.40% 10-K · filed 2023-03-29 | |||
| 2021-09-30 | 1.10% 10-Q · filed 2022-11-14 | 1.20% 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | 1.20% 10-Q · filed 2022-08-15 | 1.20% 10-Q · filed 2022-08-15 | ||
| 2020-12-31 | 1.50% 10-K · filed 2022-03-30 | |||
| 2020-09-30 | 1.50% 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | 1.50% 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |